Daewon Pharmaceutical Co., Ltd.
KSC: 003220.KS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Korea Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Seung-Ryel Baek
- Employees
- 1,260
- Headquarters
- Seoul, South Korea
- IPO year
- 2005
- Market cap
- ₩218.2B
- Website
- https://www.daewonpharm.com
Loading 003220…
Loading profile data…Frequently asked questions about 003220
What does Daewon Pharmaceutical Co., Ltd. (003220.KS) do?
Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, produces and sells medicine and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis uses. The company's principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product...
Where does 003220.KS trade?
Daewon Pharmaceutical Co., Ltd. (003220.KS) trades on the Korea Exchange.
What sector is 003220.KS in?
Daewon Pharmaceutical Co., Ltd. (003220.KS) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Daewon Pharmaceutical Co., Ltd.?
Seung-Ryel Baek is the chief executive officer of Daewon Pharmaceutical Co., Ltd. (003220.KS).
Where is Daewon Pharmaceutical Co., Ltd. headquartered?
Daewon Pharmaceutical Co., Ltd. is headquartered in South Korea.
Does 003220.KS pay a dividend?
Yes — Daewon Pharmaceutical Co., Ltd. (003220.KS) paid a trailing twelve-month dividend of KRW 250.00 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 003220.KS go public?
Daewon Pharmaceutical Co., Ltd. (003220.KS) completed its initial public offering in 2005.